Kalvista Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
KalVista Pharmaceuticals, Inc. announces its upcoming Annual Meeting on October 1, 2025, to vote on director elections, auditor ratification, and executive compensation.
NASDAQ
KalVista Pharmaceuticals, Inc. announced its Annual Meeting of Stockholders for October 1, 2025, following recent FDA and UK approvals for EKTERLY (sebetralstat) and new commercialization deals.
NASDAQ
KalVista Pharmaceuticals has scheduled its annual stockholder meeting for October 3, 2024, outlining proposals for director elections, auditor ratification, and executive compensation approval.
NASDAQ
KalVista Pharmaceuticals will hold its annual stockholders meeting virtually on October 3, 2024, to vote on director elections, auditor ratification, and executive compensation.